Lymphoma & Plasma Cell Disorders
News
Novel risk factors for febrile neutropenia in NHL, other cancers
A retrospective study has revealed new potential risk factors for chemotherapy-induced febrile neutropenia (FN) in patients with solid tumors and...
News
Palliative care guidelines relevant for hematologists, doc says
The latest edition of the national palliative care guidelines provides new clinical strategies relevant to hematology practice in the United...
From the Journals
Checkpoint inhibitor plus rituximab is active in non-Hodgkin lymphoma
Mainly low-grade toxic effects were seen on treatment with Hu5F9-G4 and rituximab in the study of relapsed and refractory patients.
Community Translations
Venetoclax approved to treat CLL patients regardless of genotype
From the Journals
Line complications plague dose-adjusted EPOCH-R in non-Hodgkin lymphoma
The risk of line-associated complications was significantly higher with dose-adjusted EPOCH-R therapy, compared with R-CHOP, in patients with...
From the Journals
First-line bortezomib prolongs survival in MCL
The survival benefits are promising with the addition of bortezomib, but there was no significant difference among high-risk patients.
News
‘Mechanoprimed’ MSCs aid hematopoietic recovery
Specially grown mesenchymal stromal cells (MSCs) can improve hematopoietic recovery, according to preclinical research published in Stem Cell...
News
Combo can prolong overall survival in MCL
Final results of a phase 3 trial suggest bortezomib plus rituximab and chemotherapy can significantly improve overall survival (OS) in transplant-...
From the Journals
Older age predicts mortality after alloHCT in NHL, but not relapse
The researchers said older age was an independent risk factor for nonrelapse mortality.
Conference Coverage
When to choose stem cell transplant in PTCL
DUBROVNIK, CROATIA – Dr. Ali Bazarbachi gives his tips for when to use allo- versus auto-HSCT in patients with peripheral T-cell lymphomas.
News
Age limits restrict AYA participation in relevant trials
MUNICH—Age limits imposed in European countries can prevent adolescents and young adults (AYAs) from enrolling in appropriate clinical trials, a...